A Multi-center, Phase 2 Study Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, a Recombinant Variant of Human APC, in Combination With tPA, Mechanical Thrombectomy or Both in Moderate to Severe Acute Ischemic Stroke
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs 3K3A APC (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms RHAPSODY
- Sponsors ZZ Biotech
- 06 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 13 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017.